Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC
Bayer/Orion’s Nubeqa Also Cleared For Prostate Cancer
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
